头盔式无创通气与常规呼吸支持对COVID-19所致急性低氧性呼吸衰竭患者死亡率的影响:HELMET-COVID随机临床试验
这项在沙特阿拉伯和科威特8个中心开展的多中心实用随机临床试验纳入320例COVID-19疑似或确诊所致急性低氧性呼吸衰竭成人患者,比较头盔式无创通气与常规呼吸支持。28天全因死亡率头盔组27.0% vs 常规组26.1%(风险差1.0%,95%CI -8.7%至10.6%;RR 1.04,95%CI 0.72-1.49;P=.85),无显著差异。作者认为头盔式无创通气未显著降低28天死亡率,但效应估计不精确,不能排除潜在的临床重要获益或 harm。
要点
- 头盔式无创通气组28天死亡率27.0%,常规呼吸支持组26.1%,组间无显著差异(P=.85)。
- 28天内气管插管率头盔组47.2% vs 常规组50.3%,风险差-3.1%(95%CI -14.1%至7.8%),无显著差异。
- 所有预设次要终点两组间均无显著差异;作者指出效应估计不精确,不能排除潜在临床重要获益或 harm。
核心结论
- 作者认为,在COVID-19肺炎所致急性低氧性呼吸衰竭患者中,头盔式无创通气与常规呼吸支持相比未显著降低28天死亡率。
- 作者指出,由于效应估计不精确,不能排除潜在的临床重要获益或 harm。
研究设计与样本
- 多中心、实用性、随机临床试验,在沙特阿拉伯和科威特8个中心开展,时间2021年2月8日至2021年11月16日。
- 纳入320例COVID-19疑似或确诊所致急性低氧性呼吸衰竭成人患者,随机分配至头盔式无创通气组(n=159)或常规呼吸支持组(n=161)。
- 常规呼吸支持包括面罩无创通气、经鼻高流量氧疗和标准氧疗;主要终点为28天全因死亡率,最终随访日期为2021年12月14日。
主要发现
- 28天内头盔式无创通气组159例中43例(27.0%)死亡,常规呼吸支持组161例中42例(26.1%)死亡(风险差1.0%[95%CI -8.7%至10.6%];相对风险1.04[95%CI 0.72-1.49];P=.85)。
- 28天内头盔式无创通气组159例中75例(47.2%)需要气管插管,常规呼吸支持组161例中81例(50.3%)需要气管插管(风险差-3.1%[95%CI -14.1%至7.8%];相对风险0.94[95%CI 0.75-1.17])。
- 气压伤在头盔式无创通气组159例中30例(18.9%)发生,常规呼吸支持组161例中25例(15.5%)发生。
- 皮肤压力性损伤在头盔式无创通气组159例中5例(3.1%)发生,常规呼吸支持组161例中10例(6.2%)发生。
- 严重不良事件在头盔式无创通气组发生2例,常规呼吸支持组发生1例;所有预设次要终点两组间均无显著差异。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 作者指出,由于效应估计不精确,不能排除潜在的临床重要获益或 harm。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Helmet noninvasive ventilation has been used in patients with COVID-19 with the premise that helmet interface is more effective than mask interface in delivering prolonged treatments with high positive airway pressure, but data about its effectiveness are limited. OBJECTIVE: To evaluate whether helmet noninvasive ventilation compared with usual respiratory support reduces mortality in patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, pragmatic, randomized clinical trial that was conducted in 8 sites in Saudi Arabia and Kuwait between February 8, 2021, and November 16, 2021. Adult patients with acute hypoxemic respiratory failure (n = 320) due to suspected or confirmed COVID-19 were included. The final follow-up date for the primary outcome was December 14, 2021. INTERVENTIONS: Patients were randomized to receive helmet noninvasive ventilation (n = 159) or usual respiratory support (n = 161), which included mask noninvasive ventilation, high-flow nasal oxygen, and standard oxygen. MAIN OUTCOMES AND MEASURES: The primary outcome was 28-day all-cause mortality. There were 12 prespecified secondary outcomes, including endotracheal intubation, barotrauma, skin pressure injury, and serious adverse events. RESULTS: Among 322 patients who were randomized, 320 were included in the primary analysis, all of whom completed the trial. Median age was 58 years, and 187 were men (58.4%). Within 28 days, 43 of 159 patients (27.0%) died in the helmet noninvasive ventilation group compared with 42 of 161 (26.1%) in the usual respiratory support group (risk difference, 1.0% [95% CI, -8.7% to 10.6%]; relative risk, 1.04 [95% CI, 0.72-1.49]; P = .85). Within 28 days, 75 of 159 patients (47.2%) required endotracheal intubation in the helmet noninvasive ventilation group compared with 81 of 161 (50.3%) in the usual respiratory support group (risk difference, -3.1% [95% CI, -14.1% to 7.8%]; relative risk, 0.94 [95% CI, 0.75-1.17]). There were no significant differences between the 2 groups in any of the prespecified secondary end points. Barotrauma occurred in 30 of 159 patients (18.9%) in the helmet noninvasive ventilation group and 25 of 161 (15.5%) in the usual respiratory support group. Skin pressure injury occurred in 5 of 159 patients (3.1%) in the helmet noninvasive ventilation group and 10 of 161 (6.2%) in the usual respiratory support group. There were 2 serious adverse events in the helmet noninvasive ventilation group and 1 in the usual respiratory support group. CONCLUSIONS AND RELEVANCE: Results of this study suggest that helmet noninvasive ventilation did not significantly reduce 28-day mortality compared with usual respiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia. However, interpretation of the findings is limited by imprecision in the effect estimate, which does not exclude potentially clinically important benefit or harm. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04477668.
引用
- Arabi YM, Aldekhyl S, Al Qahtani S, et al. Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial. JAMA. 2022. PMID: 36125473. doi:10.1001/jama.2022.15599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。